

Global Antiplatelet Drugs Market Report and Forecast 2023-2031

Market Report | 2023-04-21 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Antiplatelet Drugs Market Report and Forecast 2023-2031

Global Antiplatelet Drugs Market Outlook

The global antiplatelet drugs market size attained a value of USD 2.2 billion in 2022. The market is anticipated to grow at a CAGR of 7.8% during the forecast period of 2023-2031 to attain a value of USD 4.2 billion by 2031.

Antiplatelet Drugs Market: Introduction

Antiplatelet drugs, also known as platelet aggregation inhibitors, are a class of medications that help prevent the formation of blood clots by inhibiting the aggregation or clumping of platelets in the blood. Platelets are small blood cell fragments that play a crucial role in blood coagulation and wound healing. However, excessive platelet aggregation can lead to the formation of blood clots, which can cause life-threatening conditions such as heart attacks, strokes, or deep vein thrombosis.

Antiplatelet drugs work by blocking specific enzymes or receptors involved in the platelet activation and aggregation process, thereby reducing the likelihood of clot formation. These medications are commonly prescribed for individuals at risk of blood clot-related complications, such as those with a history of heart attack, stroke, or peripheral artery disease, or those undergoing certain medical procedures like angioplasty or stent placement.

Some common antiplatelet drugs include:

1. ☐ **Aspirin:** This widely used medication is an anti-inflammatory and analgesic drug that also exhibits antiplatelet properties. Aspirin inhibits the enzyme cyclooxygenase-1 (COX-1), which is responsible for the production of thromboxane A2, a substance that promotes platelet aggregation.
2. ☐ **Clopidogrel (Plavix):** Clopidogrel is a thienopyridine class drug that inhibits the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets. This receptor plays a crucial role in platelet activation and aggregation. By blocking this receptor, clopidogrel prevents ADP-induced platelet aggregation.
3. ☐ **Prasugrel (Effient) and Ticagrelor (Brilinta):** These drugs are also P2Y12 inhibitors, similar to clopidogrel, but with different pharmacological properties and mechanisms of action. They are generally considered more potent and faster-acting than

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

clopidogrel.

4. ☐ Dipyridamole: This drug works by inhibiting the enzyme phosphodiesterase, which results in increased levels of cyclic adenosine monophosphate (cAMP) within platelets. Elevated cAMP levels lead to reduced platelet activation and aggregation.

It is important to note that while antiplatelet drugs can be beneficial in preventing blood clot formation, they can also increase the risk of bleeding complications. Therefore, the use of these medications must be carefully managed and monitored by healthcare professionals, considering the patient's individual risk factors and medical history.

Antiplatelet Drugs Market Segmentations

The market can be categorised into drug, drug class, application, route of administration, distribution channel, and region

Antiplatelet Drugs Market Breakup by Drug

- ☐ Aspirin
- ☐ Clopidogrel
- ☐ Ticagrelor
- ☐ Prasugrel
- ☐ Dipyridamole
- ☐ Ticlopidine
- ☐ Abciximab
- ☐ Tirofiban
- ☐ Others

Antiplatelet Drugs Market Breakup by Drug Class

- ☐ Platelet Aggregation Inhibitors
- ☐ Glycoprotein Platelet Inhibitors
- ☐ Protease-Activated Receptor-1 Antagonists
- ☐ Others

Antiplatelet Drugs Market Breakup by Application

- ☐ Myocardial Infraction
- ☐ Percutaneous Coronary Interventions
- ☐ Angioplasty
- ☐ Arterial Thrombosis
- ☐ Dental Surgeries
- ☐ Others

Antiplatelet Drugs Market Breakup by Route of Administration

- ☐ Oral
- ☐ Injectables

Antiplatelet Drugs Market Breakup by Distribution

- ☐ Market Overview
- ☐ Hospital Pharmacy
- ☐ Retail Pharmacy
- ☐ Online Pharmacy
- ☐ Others

Antiplatelet Drugs Market Breakup by Region

- ☐ North America
- ☐ United States of America
- ☐ Canada
- ☐ Europe
- ☐ United Kingdom
- ☐ Germany

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Antiplatelet Drugs Market Scenario

The global antiplatelet drugs market is witnessing significant growth, driven by the increasing prevalence of cardiovascular diseases, such as heart attacks, strokes, and peripheral arterial diseases. Antiplatelet drugs are medications that inhibit platelet aggregation, preventing blood clots from forming, and subsequently reducing the risk of heart attacks and strokes. The market encompasses a wide range of products, including P2Y12 inhibitors, COX-1 inhibitors, and glycoprotein IIb/IIIa inhibitors, among others.

Market Drivers

Several factors are propelling the growth of the antiplatelet drugs market. The rising aging population, coupled with lifestyle changes, such as unhealthy diets and sedentary lifestyles, have led to a higher prevalence of cardiovascular diseases. Furthermore, the increasing awareness regarding preventive healthcare measures and advancements in medical research, leading to the development of new and more effective antiplatelet drugs, are contributing to the expansion of the market.

Market Challenges

Despite the promising growth, the antiplatelet drugs market faces certain challenges. The risk of side effects, such as excessive bleeding, can limit the usage of these medications. Additionally, the high cost of drug development and stringent regulatory requirements may hinder the introduction of new products to the market. Moreover, the presence of alternative treatments, such as anticoagulants and thrombolytic agents, creates competition and may affect the market share of antiplatelet drugs.

Regional Analysis

Geographically, the global antiplatelet drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market due to its advanced healthcare infrastructure, high awareness about cardiovascular diseases, and the presence of key market players. Europe follows closely, with Asia-Pacific anticipated to be the fastest-growing region, owing to the increasing prevalence of cardiovascular diseases, growing healthcare expenditure, and improving healthcare infrastructure.

Future Outlook

The antiplatelet drugs market is expected to witness sustained growth in the coming years, primarily driven by the increasing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

prevalence of cardiovascular diseases and the development of novel therapeutics. The advent of precision medicine and genomics may lead to the development of tailored antiplatelet therapies, offering improved efficacy and safety profiles. Additionally, emerging markets in the Asia-Pacific region present significant growth opportunities for the market.

Key Players in the Global Antiplatelet Drugs Market

The report gives an in-depth analysis of the key players involved in the antiplatelet drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Glenmark Pharmaceuticals Ltd.
- Sanofi SA
- Pfizer Inc.
- Baxter International Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Bausch Health Companies Inc.?
- Johnson & Johnson Private Limited
- Bristol-Myers Squibb Company
- DAIICHI SANKYO COMPANY, LIMITED
- Otsuka America Pharmaceutical, Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Genentech, Inc.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Antiplatelet Drugs Market Overview
 - 3.1 Global Antiplatelet Drugs Market Historical Value (2016-2022)
 - 3.2 Global Antiplatelet Drugs Market Forecast Value (2023-2031)
- 4 Global Antiplatelet Drugs Market Landscape
 - 4.1 Global Antiplatelet Drugs Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Antiplatelet Drugs Product Landscape
 - 4.2.1 Analysis by Drug
 - 4.2.2 Analysis by Drug Class

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.3 Analysis by Application
- 4.2.4 Analysis by Route of Application
- 4.2.5 Analysis by Distribution Channel
- 5 Global Antiplatelet Drugs Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Antiplatelet Drugs Market Segmentation
 - 6.1 Global Antiplatelet Drugs Market by Drug
 - 6.1.1 Market Overview
 - 6.1.2 Aspirin
 - 6.1.3 Clopidogrel
 - 6.1.4 Ticagrelor
 - 6.1.5 Prasugrel
 - 6.1.6 Dipyridamole
 - 6.1.7 Ticlopidine
 - 6.1.8 Abciximab
 - 6.1.9 Tirofiban
 - 6.1.10 Others
 - 6.2 Global Antiplatelet Drugs Market by Drug Class
 - 6.2.1 Market Overview
 - 6.2.2 Platelet Aggregation Inhibitors
 - 6.2.3 Glycoprotein Platelet Inhibitors
 - 6.2.4 Protease-Activated Receptor-1 Antagonists
 - 6.2.5 Others
 - 6.3 Global Antiplatelet Drugs Market by Application
 - 6.3.1 Market Overview
 - 6.3.2 Myocardial Infraction
 - 6.3.3 Percutaneous Coronary Interventions
 - 6.3.4 Angioplasty
 - 6.3.5 Arterial Thrombosis
 - 6.3.6 Dental Surgeries
 - 6.3.7 Others
 - 6.4 Global Antiplatelet Drugs Market by Route of Administration
 - 6.4.1 Market Overview
 - 6.4.2 Oral
 - 6.4.3 Injectables
 - 6.5 Global Antiplatelet Drugs Market by Distribution Channel
 - 6.5.1 Market Overview
 - 6.5.2 Hospital Pharmacy
 - 6.5.3 Retail Pharmacy
 - 6.5.4 Online Pharmacy
 - 6.5.5 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.6 Global Antiplatelet Drugs Market by Region
 - 6.6.1 Market Overview
 - 6.6.2 North America
 - 6.6.3 Europe
 - 6.6.4 Asia Pacific
 - 6.6.5 Latin America
 - 6.6.6 Middle East and Africa
- 7 North America Antiplatelet Drugs Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Antiplatelet Drugs Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Antiplatelet Drugs Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Antiplatelet Drugs Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Antiplatelet Drugs Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
 - 14.1 Analysis by Trial Registration Year
 - 14.2 Analysis by Trial Status
 - 14.3 Analysis by Trial Phase
 - 14.4 Analysis by Therapeutic Area
 - 14.5 Analysis by Geography
- 15 Funding Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players
 - 15.5 Analysis by Leading Investors
 - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players
 - 16.4 Analysis by Geography
- 17 Regulatory Framework
 - 17.1 Regulatory Overview
 - 17.1.1 US FDA
 - 17.1.2 EU EMA
 - 17.1.3 INDIA CDSCO
 - 17.1.4 JAPAN PMDA
 - 17.1.5 Others
- 18 Supplier Landscape
 - 18.1 Glenmark Pharmaceuticals Ltd.
 - 18.1.1 Financial Analysis
 - 18.1.2 Product Portfolio
 - 18.1.3 Demographic Reach and Achievements
 - 18.1.4 Mergers and Acquisitions
 - 18.1.5 Certifications
 - 18.2 Sanofi SA
 - 18.2.1 Financial Analysis
 - 18.2.2 Product Portfolio
 - 18.2.3 Demographic Reach and Achievements
 - 18.2.4 Mergers and Acquisitions
 - 18.2.5 Certifications
 - 18.3 Pfizer Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Baxter International Inc.
 - 18.4.1 Financial Analysis
 - 18.4.2 Financial Portfolio
 - 18.4.3 Demographic Reach and Achievements
 - 18.4.4 Mergers and Acquisitions
 - 18.4.5 Certifications
- 18.5 Bayer AG
 - 18.5.1 Financial Analysis
 - 18.5.2 Product Portfolio
 - 18.5.3 Demographic Reach and Achievements
 - 18.5.4 Mergers and Acquisitions
 - 18.5.5 Certifications
- 18.6 F. Hoffmann-La Roche Ltd.
 - 18.6.1 Financial Analysis
 - 18.6.2 Product Portfolio
 - 18.6.3 Demographic Reach and Achievements
 - 18.6.4 Mergers and Acquisitions
 - 18.6.5 Certifications
- 18.7 Teva Pharmaceutical Industries Ltd.
 - 18.7.1 Financial Analysis
 - 18.7.2 Product Portfolio
 - 18.7.3 Demographic Reach and Achievements
 - 18.7.4 Mergers and Acquisitions
 - 18.7.5 Certifications
- 18.8 Mylan N.V.
 - 18.8.1 Financial Analysis
 - 18.8.2 Product Portfolio
 - 18.8.3 Demographic Reach and Achievements
 - 18.8.4 Mergers and Acquisitions
 - 18.8.5 Certifications
- 18.9 Bausch Health Companies Inc.
 - 18.9.1 Financial Analysis
 - 18.9.2 Product Portfolio
 - 18.9.3 Demographic Reach and Achievements
 - 18.9.4 Mergers and Acquisitions
 - 18.9.5 Certifications
- 18.10 Johnson & Johnson Private Limited
 - 18.10.1 Financial Analysis
 - 18.10.2 Product Portfolio
 - 18.10.3 Demographic Reach and Achievements
 - 18.10.4 Mergers and Acquisitions
 - 18.10.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.11 Bristol-Myers Squibb Company
 - 18.11.1 Financial Analysis
 - 18.11.2 Product Portfolio
 - 18.11.3 Demographic Reach and Achievements
 - 18.11.4 Mergers and Acquisitions
 - 18.11.5 Certifications
- 18.12 DAIICHI SANKYO COMPANY, LIMITED
 - 18.12.1 Financial Analysis
 - 18.12.2 Product Portfolio
 - 18.12.3 Demographic Reach and Achievements
 - 18.12.4 Mergers and Acquisitions
 - 18.12.5 Certifications
- 18.13 Otsuka America Pharmaceutical, Inc.
 - 18.13.1 Financial Analysis
 - 18.13.2 Product Portfolio
 - 18.13.3 Demographic Reach and Achievements
 - 18.13.4 Mergers and Acquisitions
 - 18.13.5 Certifications
- 18.14 Eli Lilly and Company
 - 18.14.1 Financial Analysis
 - 18.14.2 Product Portfolio
 - 18.14.3 Demographic Reach and Achievements
 - 18.14.4 Mergers and Acquisitions
 - 18.14.5 Certifications
- 18.15 AbbVie Inc.
 - 18.15.1 Financial Analysis
 - 18.15.2 Product Portfolio
 - 18.15.3 Demographic Reach and Achievements
 - 18.15.4 Mergers and Acquisitions
 - 18.15.5 Certifications
- 18.16 Genentech, Inc.
 - 18.16.1 Financial Analysis
 - 18.16.2 Product Portfolio
 - 18.16.3 Demographic Reach and Achievements
 - 18.16.4 Mergers and Acquisitions
 - 18.16.5 Certifications
- 19 Global Antiplatelet Drugs Market - Distribution Model (Additional Insight)
 - 19.1 Overview
 - 19.2 Potential Distributors
 - 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
 - 21.1 Very Small Companies
 - 21.2 Small Companies
 - 21.3 Mid-Sized Companies
 - 21.4 Large Companies
 - 21.5 Very Large Companies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

22 Payment Methods (Additional Insight)

22.1 Government Funded

22.2 Private Insurance

22.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Antiplatelet Drugs Market Report and Forecast 2023-2031

Market Report | 2023-04-21 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com